Pharmacophore modeling and virtual screening to design the potential influenza virus endonuclease inhibitors

Huang Sheng Liao, Josephine W. Wu, Hsuan Liang Liu, Jian Hua Zhao, Cheng Wen Tsao, Kung Tien Liu, Chih Kuang Chuang, Hsin Yi Lin, Wei Bor Tsai, Yih Ho

Research output: Contribution to journalArticle

Abstract

Influenza virus endonuclease is an attractive target for antiviral therapy in the treatment of influenza infection. The purpose of this study is to design a novel antiviral agent with improved biological activities against the influenza virus endonuclease. In this study, chemical feature-based 3D pharmacophoremodels were developed from 41 known influenza virus endonuclease inhibitors. The best quantitative pharmacophore model (Hypo1), which consists of two hydrogen-bond acceptors and two hydrophobic features, yields the highest correlation coefficient (R = 0.886). Hypo1 was further validated by the cross validation method and the test set compounds. The application of this model for predicting the activities of 11 known influenza virus endonuclease inhibitors in the test set shows great success. The correlation coefficient of 0.942 and a cross validation of 95% confidence level prove that this model is reliable in identifying structurally diverse compounds for influenza virus endonuclease inhibition. The most active compound (compound 1) from the training set was docked into the active site of the influenza virus endonuclease as an additional verification that the pharmacophore model is accurate. The docked conformation showed important hydrogen bond interactions between the compound and two amino acids, Lys134 and Lys137. After validation, this model was used to screen the NCI chemical database to identify new influenza virus endonuclease inhibitors. Our study shows that the top ranking compound out of the 10 newly identified compounds using fit value ranking has an estimated activity of 0.049 μM. These newly identified lead compounds can be further experimentally validated using in vitro techniques.

Original languageEnglish
Pages (from-to)1430-1438
Number of pages9
JournalJournal of the Chinese Chemical Society
Volume59
Issue number11
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Endonucleases
Viruses
Screening
Antiviral Agents
Hydrogen bonds
Lead compounds
Bioactivity
Conformations
Amino Acids

Keywords

  • Endonuclease inhibitors
  • Influenza virus endonuclease
  • Pharmacophore model

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Pharmacophore modeling and virtual screening to design the potential influenza virus endonuclease inhibitors. / Liao, Huang Sheng; Wu, Josephine W.; Liu, Hsuan Liang; Zhao, Jian Hua; Tsao, Cheng Wen; Liu, Kung Tien; Chuang, Chih Kuang; Lin, Hsin Yi; Tsai, Wei Bor; Ho, Yih.

In: Journal of the Chinese Chemical Society, Vol. 59, No. 11, 11.2012, p. 1430-1438.

Research output: Contribution to journalArticle

Liao, HS, Wu, JW, Liu, HL, Zhao, JH, Tsao, CW, Liu, KT, Chuang, CK, Lin, HY, Tsai, WB & Ho, Y 2012, 'Pharmacophore modeling and virtual screening to design the potential influenza virus endonuclease inhibitors', Journal of the Chinese Chemical Society, vol. 59, no. 11, pp. 1430-1438. https://doi.org/10.1002/jccs.201100390
Liao, Huang Sheng ; Wu, Josephine W. ; Liu, Hsuan Liang ; Zhao, Jian Hua ; Tsao, Cheng Wen ; Liu, Kung Tien ; Chuang, Chih Kuang ; Lin, Hsin Yi ; Tsai, Wei Bor ; Ho, Yih. / Pharmacophore modeling and virtual screening to design the potential influenza virus endonuclease inhibitors. In: Journal of the Chinese Chemical Society. 2012 ; Vol. 59, No. 11. pp. 1430-1438.
@article{e9b6ca67879d49abb9b8b31550dbac33,
title = "Pharmacophore modeling and virtual screening to design the potential influenza virus endonuclease inhibitors",
abstract = "Influenza virus endonuclease is an attractive target for antiviral therapy in the treatment of influenza infection. The purpose of this study is to design a novel antiviral agent with improved biological activities against the influenza virus endonuclease. In this study, chemical feature-based 3D pharmacophoremodels were developed from 41 known influenza virus endonuclease inhibitors. The best quantitative pharmacophore model (Hypo1), which consists of two hydrogen-bond acceptors and two hydrophobic features, yields the highest correlation coefficient (R = 0.886). Hypo1 was further validated by the cross validation method and the test set compounds. The application of this model for predicting the activities of 11 known influenza virus endonuclease inhibitors in the test set shows great success. The correlation coefficient of 0.942 and a cross validation of 95{\%} confidence level prove that this model is reliable in identifying structurally diverse compounds for influenza virus endonuclease inhibition. The most active compound (compound 1) from the training set was docked into the active site of the influenza virus endonuclease as an additional verification that the pharmacophore model is accurate. The docked conformation showed important hydrogen bond interactions between the compound and two amino acids, Lys134 and Lys137. After validation, this model was used to screen the NCI chemical database to identify new influenza virus endonuclease inhibitors. Our study shows that the top ranking compound out of the 10 newly identified compounds using fit value ranking has an estimated activity of 0.049 μM. These newly identified lead compounds can be further experimentally validated using in vitro techniques.",
keywords = "Endonuclease inhibitors, Influenza virus endonuclease, Pharmacophore model",
author = "Liao, {Huang Sheng} and Wu, {Josephine W.} and Liu, {Hsuan Liang} and Zhao, {Jian Hua} and Tsao, {Cheng Wen} and Liu, {Kung Tien} and Chuang, {Chih Kuang} and Lin, {Hsin Yi} and Tsai, {Wei Bor} and Yih Ho",
year = "2012",
month = "11",
doi = "10.1002/jccs.201100390",
language = "English",
volume = "59",
pages = "1430--1438",
journal = "Journal of the Chinese Chemical Society",
issn = "0009-4536",
publisher = "Chinese Chemical Society",
number = "11",

}

TY - JOUR

T1 - Pharmacophore modeling and virtual screening to design the potential influenza virus endonuclease inhibitors

AU - Liao, Huang Sheng

AU - Wu, Josephine W.

AU - Liu, Hsuan Liang

AU - Zhao, Jian Hua

AU - Tsao, Cheng Wen

AU - Liu, Kung Tien

AU - Chuang, Chih Kuang

AU - Lin, Hsin Yi

AU - Tsai, Wei Bor

AU - Ho, Yih

PY - 2012/11

Y1 - 2012/11

N2 - Influenza virus endonuclease is an attractive target for antiviral therapy in the treatment of influenza infection. The purpose of this study is to design a novel antiviral agent with improved biological activities against the influenza virus endonuclease. In this study, chemical feature-based 3D pharmacophoremodels were developed from 41 known influenza virus endonuclease inhibitors. The best quantitative pharmacophore model (Hypo1), which consists of two hydrogen-bond acceptors and two hydrophobic features, yields the highest correlation coefficient (R = 0.886). Hypo1 was further validated by the cross validation method and the test set compounds. The application of this model for predicting the activities of 11 known influenza virus endonuclease inhibitors in the test set shows great success. The correlation coefficient of 0.942 and a cross validation of 95% confidence level prove that this model is reliable in identifying structurally diverse compounds for influenza virus endonuclease inhibition. The most active compound (compound 1) from the training set was docked into the active site of the influenza virus endonuclease as an additional verification that the pharmacophore model is accurate. The docked conformation showed important hydrogen bond interactions between the compound and two amino acids, Lys134 and Lys137. After validation, this model was used to screen the NCI chemical database to identify new influenza virus endonuclease inhibitors. Our study shows that the top ranking compound out of the 10 newly identified compounds using fit value ranking has an estimated activity of 0.049 μM. These newly identified lead compounds can be further experimentally validated using in vitro techniques.

AB - Influenza virus endonuclease is an attractive target for antiviral therapy in the treatment of influenza infection. The purpose of this study is to design a novel antiviral agent with improved biological activities against the influenza virus endonuclease. In this study, chemical feature-based 3D pharmacophoremodels were developed from 41 known influenza virus endonuclease inhibitors. The best quantitative pharmacophore model (Hypo1), which consists of two hydrogen-bond acceptors and two hydrophobic features, yields the highest correlation coefficient (R = 0.886). Hypo1 was further validated by the cross validation method and the test set compounds. The application of this model for predicting the activities of 11 known influenza virus endonuclease inhibitors in the test set shows great success. The correlation coefficient of 0.942 and a cross validation of 95% confidence level prove that this model is reliable in identifying structurally diverse compounds for influenza virus endonuclease inhibition. The most active compound (compound 1) from the training set was docked into the active site of the influenza virus endonuclease as an additional verification that the pharmacophore model is accurate. The docked conformation showed important hydrogen bond interactions between the compound and two amino acids, Lys134 and Lys137. After validation, this model was used to screen the NCI chemical database to identify new influenza virus endonuclease inhibitors. Our study shows that the top ranking compound out of the 10 newly identified compounds using fit value ranking has an estimated activity of 0.049 μM. These newly identified lead compounds can be further experimentally validated using in vitro techniques.

KW - Endonuclease inhibitors

KW - Influenza virus endonuclease

KW - Pharmacophore model

UR - http://www.scopus.com/inward/record.url?scp=84872331486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872331486&partnerID=8YFLogxK

U2 - 10.1002/jccs.201100390

DO - 10.1002/jccs.201100390

M3 - Article

AN - SCOPUS:84872331486

VL - 59

SP - 1430

EP - 1438

JO - Journal of the Chinese Chemical Society

JF - Journal of the Chinese Chemical Society

SN - 0009-4536

IS - 11

ER -